Cargando…

Curative effect of anti-fibrosis Chinese patent medicines combined with ursodeoxycholic acid for primary biliary cholangitis: A systematic review and meta-analysis

Objective: To delineate the curative effect and safety of anti-fibrosis Chinese patent medicines (CPMs) combined with ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC). Methods: A literature search was conducted using PubMed, Web of Science, Embase, Cochrane Library, Wanfang database...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bi, Yufei, Shi, Ke, Chen, Jialiang, Wang, Xianbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070848/ https://www.ncbi.nlm.nih.gov/pubmed/37025490 http://dx.doi.org/10.3389/fphar.2023.1159222

Ejemplares similares

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study
por: Cançado, Guilherme Grossi Lopes, et al.
Publicado: (2022)

Efficacy and safety of fenofibrate add-on therapy in patients with primary biliary cholangitis refractory to ursodeoxycholic acid: A retrospective study and updated meta-analysis
por: Guoyun, Xuan, et al.
Publicado: (2022)

Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis
por: Shu, Yanyun, et al.
Publicado: (2021)

External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: Cheung, Angela C., et al.
Publicado: (2018)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019)

Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review
por: Li, Xuan, et al.
Publicado: (2020)

Looking Into the Crystal Ball: Predicting Non-response to Ursodeoxycholic Acid in Primary Biliary Cholangitis
por: Zimmer, Vincent, et al.
Publicado: (2016)

Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis
por: Wang, Zi-Long, et al.
Publicado: (2022)

Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2(−/−) mice and human primary sclerosing cholangitis
por: Meng, Fanyin, et al.
Publicado: (2018)

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis
por: Martinez-Gili, Laura, et al.
Publicado: (2023)

Evaluation of LiangXue JieDu Therapy in Combination With Western Medicine for Acute-On-Chronic Liver Failure: A Systematic Review and meta-Analysis
por: Shi, Ke, et al.
Publicado: (2022)

Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid
por: Cheung, Ka-Shing, et al.
Publicado: (2017)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid
por: Li, Chunlei, et al.
Publicado: (2022)

Efficacy and Safety of Chinese Patent Medicine for the Prevention and Treatment of Radiotherapy and Chemotherapy-Induced Oral Mucositis: A Systematic Review and Meta-Analysis
por: Xie, Yufei, et al.
Publicado: (2022)

Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials
por: Agrawal, Rohit, et al.
Publicado: (2019)

A 60-Year-Old Woman with Primary Biliary Cholangitis and Crohn’s Ileitis Following the Suspension of Ursodeoxycholic Acid
por: Romeo, Mario, et al.
Publicado: (2022)

Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid
por: Ding, Dawei, et al.
Publicado: (2022)

Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion
por: Yang, Chunmei, et al.
Publicado: (2022)

Efficacy of ursodeoxycholic acid for primary biliary cholangitis: Experience from a tertiary care centre in Saudi Arabia
por: AlWabel, Ahmed H, et al.
Publicado: (2022)

Effects of adjuvant huaier granule therapy on survival rate of patients with hepatocellular carcinoma
por: Shi, Ke, et al.
Publicado: (2023)

Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis
por: Ni, Ping, et al.
Publicado: (2019)

Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease
por: Cortez‐Pinto, Helena, et al.
Publicado: (2021)

Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients
por: Wang, Zi-Long, et al.
Publicado: (2022)

Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China
por: Zhuang, Wei, et al.
Publicado: (2020)

Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review
por: Yang, Zhi-Hua, et al.
Publicado: (2021)

Efficacy and Safety of Chinese Patent Medicine Combined With Oseltamivir in Treatment of Children With Influenza: A meta-Analysis
por: Duan, Nai-fan, et al.
Publicado: (2021)

NI‐0801, an anti‐chemokine (C‐X‐C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid
por: de Graaf, Kathy L., et al.
Publicado: (2018)

Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis
por: Xiang, Xinyu, et al.
Publicado: (2021)

Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: de Veer, Rozanne C., et al.
Publicado: (2022)

Ursodeoxycholic Acid Treatment–Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis
por: de Veer, Rozanne C., et al.
Publicado: (2023)

Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study
por: Chang, Jong-In, et al.
Publicado: (2023)

Clinical Progress on Management of Pneumonia Due to COVID-19 With Chinese Traditional Patent Medicines
por: Wu, Ying, et al.
Publicado: (2021)

Corrigendum: Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review
por: Yang, Zhi-Hua, et al.
Publicado: (2021)

Treatment of primary biliary cirrhosis with ursodeoxycholic acid combined with traditional Chinese medicine: A protocol for systematic review and meta analysis
por: Chen, Xing, et al.
Publicado: (2020)

Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis: A systematic review and meta-analysis
por: Xu, Chenyi, et al.
Publicado: (2022)

High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study
por: Zhu, Huiling, et al.
Publicado: (2023)

The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials
por: Huang, Peiying, et al.
Publicado: (2022)

An Efficacy and Feasibility Analysis of Chinese Patent Medicine Combined With Letrozole in the Treatment of Women With Ovulation Disorders: A Network Meta-Analysis
por: Zhu, Jing-Yan, et al.
Publicado: (2021)

A Retrospective Study on the Use of Chinese Patent Medicine in 24 Medical Institutions for COVID-19 in China
por: Zhang, Nan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hdaefsad2o9eigeedn7a32d8tm